Login to Your Account



FDA Advisory Committee Gives Thumbs Up to Gattex in SBS

By Catherine Shaffer
Staff Writer

Tuesday, October 16, 2012

The FDA's Gastrointestinal Drugs Advisory Committee (GIDAC) voted unanimously Tuesday that the benefits of NPS Pharmaceuticals Inc.'s Gattex (teduglutide) for short bowel syndrome (SBS) outweighed its risks, and that the drug should be approved.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription